Float Short %

7.09

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

-0.06

EPS Last/This Y

0.13

EPS This/Next Y

Price

4.46

Target Price

5.25

Analyst Recom

1.5

Performance Q

24.58

Relative Volume

1.68

Beta

1.07

Ticker: ABUS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ABUS	3.36	0.19	1.60	33659
2025-08-18	ABUS	3.38	0.20	0.00	27932
2025-08-19	ABUS	3.5	0.20	0.00	27970
2025-08-20	ABUS	3.49	0.20	0.00	28184
2025-08-21	ABUS	3.58	0.20	0.01	28564
2025-08-22	ABUS	3.59	0.20	0.00	28599
2025-08-25	ABUS	3.5	0.20	0.05	28609
2025-08-26	ABUS	3.65	0.19	0.04	28800
2025-08-27	ABUS	3.65	0.19	0.13	28928
2025-08-28	ABUS	3.67	0.20	0.00	28947
2025-08-29	ABUS	3.71	0.20	0.00	28961
2025-09-02	ABUS	3.82	0.19	0.27	29057
2025-09-03	ABUS	3.93	0.20	0.03	29354
2025-09-04	ABUS	4.02	0.20	0.00	29519
2025-09-05	ABUS	4.19	0.19	0.15	29752
2025-09-08	ABUS	4.09	0.19	0.00	30911
2025-09-09	ABUS	4.35	0.19	0.00	30956
2025-09-10	ABUS	4.61	0.18	0.09	31939
2025-09-11	ABUS	4.9	0.18	0.01	33321
2025-09-12	ABUS	4.47	0.16	0.61	37326
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ABUS	3.37	50.2	-	-0.25
2025-08-18	ABUS	3.38	67.0	-	-0.25
2025-08-19	ABUS	3.49	67.0	-	-0.25
2025-08-20	ABUS	3.50	67.0	-	-0.25
2025-08-21	ABUS	3.58	67.0	-	-0.25
2025-08-22	ABUS	3.59	67.0	-	-0.25
2025-08-25	ABUS	3.51	67.0	-	-0.25
2025-08-26	ABUS	3.65	67.0	-	-0.25
2025-08-27	ABUS	3.66	67.0	-	-0.25
2025-08-28	ABUS	3.66	67.0	-	-0.25
2025-08-29	ABUS	3.71	67.0	-	-0.25
2025-09-02	ABUS	3.81	67.0	-	-0.25
2025-09-03	ABUS	3.94	67.0	-	-0.25
2025-09-04	ABUS	4.02	67.0	-	-0.25
2025-09-05	ABUS	4.20	67.0	-	-0.25
2025-09-08	ABUS	4.09	67.0	-	-0.25
2025-09-09	ABUS	4.35	67.0	-	-0.25
2025-09-10	ABUS	4.62	67.0	-	-0.25
2025-09-11	ABUS	4.90	67.0	-	-0.25
2025-09-12	ABUS	4.46	67.0	-	-0.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ABUS	0.00	7.45	8.73
2025-08-18	ABUS	0.00	7.24	8.73
2025-08-19	ABUS	0.00	7.24	8.73
2025-08-20	ABUS	0.00	7.24	8.73
2025-08-21	ABUS	0.00	7.24	8.73
2025-08-22	ABUS	0.00	7.24	8.73
2025-08-25	ABUS	0.00	7.15	8.73
2025-08-26	ABUS	0.00	7.15	8.73
2025-08-27	ABUS	0.00	7.15	8.41
2025-08-28	ABUS	0.00	7.15	8.41
2025-08-29	ABUS	0.00	7.15	8.41
2025-09-02	ABUS	0.00	7.15	8.41
2025-09-03	ABUS	0.00	7.15	8.41
2025-09-04	ABUS	0.00	7.15	8.41
2025-09-05	ABUS	0.00	7.15	8.41
2025-09-08	ABUS	0.00	7.16	8.41
2025-09-09	ABUS	0.00	7.16	8.41
2025-09-10	ABUS	0.00	7.16	8.41
2025-09-11	ABUS	0.00	7.16	7.09
2025-09-12	ABUS	0.00	7.16	7.09
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

-0.05

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

Institutional Transactions

7.16

Beta

1.07

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.4

Max Drawdown 5-Year %

-66

Target Price

5.25

P/E

Forward P/E

PEG

P/S

55.45

P/B

10.3

P/Free Cash Flow

EPS

-0.29

Average EPS Est. Cur. Y

-0.25

EPS Next Y. (Est.)

-0.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-351.92

Relative Volume

1.68

Return on Equity vs Sector %

-90.3

Return on Equity vs Industry %

-77.1

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

Arbutus Biopharma Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 44

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today

news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance

stock history ABUS – Arbutus Biopharma Corporation invest stock market

stock prices ABUS premarket after hours

ticker ABUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ABUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y